Friday, July 10, 2026

pharma · Steroid refractory Acute Graft versus host Disease · moderate to severe atopic dermatitis

Medac Gesellschaft fuer

Medac Gesellschaft fuer is a pharma organization headquartered in EU. Primary therapeutic focus areas include Steroid refractory Acute Graft versus host Disease, moderate to severe atopic dermatitis. NovaPharmaNews links

EU HQ
EMA registrant Type
Company details
Status
Public
HQ
EU
Programs
3
Drugs
14
Patents
0
Clinical program

MC-MSC.1/aGvHD

Phase 3 · small molecule · Steroid refractory Acute Graft versus host Disease

MC-MSC.1/aGvHD for Steroid refractory Acute Graft versus host Disease is a Phase 3 program (small_molecule) at Medac Gesellschaft fuer klinische Spezialpraeparate mbH with 1 ClinicalTrials.gov record(s).

Internal code MC-MSC.1/aGvHD

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Medac Gesellschaft fuer klinische Spezialpraeparate mbH
Phase
Phase 3
Modality
small_molecule
Indication
Steroid refractory Acute Graft versus host Disease
Status
active
Trials
1